Subcutaneous trastuzumab with pertuzumab and docetaxel in HER2-positive metastatic breast cancer: Final analysis of MetaPHER, a phase IIIb single-arm safety studySherko Kuemmel, Miguel Martín, Bartosz Itrych et al.|Breast Cancer Research and Treatment|2021Cited by 23
Subcutaneous Trastuzumab with Pertuzumab and Docetaxel in HER2-Positive Metastatic Breast Cancer: Final Analysis of MetaPHER, A Phase 3b Single-Arm Safety StudySherko Kümmel, Miguel Martín, Carlo Tondini et al.|Research Square|2020Cited by 1